Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
暂无分享,去创建一个
P. Ascierto | A. Testori | E. Simeone | P. Queirolo | M. Mandalà | M. Guida | M. Maio | P. Marchetti | G. Rinaldi | F. Cognetti | V. Ferraresi | R. Ridolfi | M. Bernengo | M. Vecchio | V. Sileni | F. De Rosa | F. Carnevale-Schianca | C. Cimminiello | L. Galli | G. C. Cappellini | V. C. Sileni | G. Cappellini
[1] M. Weichenthal,et al. Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[2] David C. Smith,et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Wolchok,et al. Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1 monoclonal antibody) in patients with advanced melanoma. , 2013 .
[4] J. Wolchok,et al. Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials. , 2013 .
[5] Dennie T. Frederick,et al. Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma , 2013, Oncoimmunology.
[6] J. Wolchok,et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. , 2013, The New England journal of medicine.
[7] P. Ascierto,et al. Do BRAF inhibitors select for populations with different disease progression kinetics? , 2013, Journal of Translational Medicine.
[8] C. Berking,et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. , 2013, The Lancet. Oncology.
[9] Michael B Atkins,et al. Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.
[10] J. Sosman,et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Ascierto,et al. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use , 2012, Journal of Translational Medicine.
[12] A. Giobbie-Hurder,et al. Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. , 2012 .
[13] S. Rosenberg,et al. CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma , 2012, Clinical Cancer Research.
[14] Nikhil Wagle,et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[16] Axel Hoos,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. , 2011, The New England journal of medicine.
[17] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[18] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[19] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[20] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Axel Hoos,et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria , 2009, Clinical Cancer Research.
[22] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .